CHMP Recommends Approval of Atara Biotherapeutics’ EbvalloTM (tabelecleucel) for the Treatment of Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease

EbvalloTM on Track to be the First Ever Allogeneic T-Cell Therapy Approved Positive Opinion Based on Pivotal Phase 3 ALLELE Study Demonstrating a Favorable Risk-Benefit Profile European Commission Approval Expected in Q4 2022 SAN FRANCISCO and CASTRES, France, Oct. 14, 2022 /PRNewswire/…

No Comments

No comments yet.

Sorry, the comment form is closed at this time.